[go: up one dir, main page]

DK3126354T3 - Halogenerede quinazolin-thf-aminer som pde1-inhibitorer - Google Patents

Halogenerede quinazolin-thf-aminer som pde1-inhibitorer Download PDF

Info

Publication number
DK3126354T3
DK3126354T3 DK15713186.3T DK15713186T DK3126354T3 DK 3126354 T3 DK3126354 T3 DK 3126354T3 DK 15713186 T DK15713186 T DK 15713186T DK 3126354 T3 DK3126354 T3 DK 3126354T3
Authority
DK
Denmark
Prior art keywords
thf
amines
pde1 inhibitors
halogenated quinazoline
quinazoline
Prior art date
Application number
DK15713186.3T
Other languages
English (en)
Inventor
Jan Kehler
Morten Langgård
Lars Kyhn Rasmussen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of DK3126354T3 publication Critical patent/DK3126354T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DK15713186.3T 2014-04-04 2015-03-27 Halogenerede quinazolin-thf-aminer som pde1-inhibitorer DK3126354T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400194 2014-04-04
PCT/EP2015/056713 WO2015150254A1 (en) 2014-04-04 2015-03-27 Halogenated quinazolin-thf-amines as pde1 inhibitors

Publications (1)

Publication Number Publication Date
DK3126354T3 true DK3126354T3 (da) 2020-03-09

Family

ID=52779655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15713186.3T DK3126354T3 (da) 2014-04-04 2015-03-27 Halogenerede quinazolin-thf-aminer som pde1-inhibitorer

Country Status (39)

Country Link
US (2) US10005764B2 (da)
EP (1) EP3126354B1 (da)
JP (1) JP6554116B2 (da)
KR (1) KR20160138084A (da)
CN (2) CN106132953B (da)
AP (1) AP2016009521A0 (da)
AR (1) AR101155A1 (da)
AU (1) AU2015239696B2 (da)
CA (1) CA2943011A1 (da)
CL (1) CL2016002515A1 (da)
CR (1) CR20160463A (da)
CY (1) CY1122784T1 (da)
DK (1) DK3126354T3 (da)
DO (1) DOP2016000263A (da)
EA (1) EA032579B1 (da)
EC (1) ECSP16082599A (da)
ES (1) ES2776359T3 (da)
GE (1) GEP20186920B (da)
GT (1) GT201600213A (da)
HR (1) HRP20200369T1 (da)
IL (1) IL248078B (da)
JO (1) JO3628B1 (da)
LT (1) LT3126354T (da)
MA (1) MA39837B1 (da)
MX (1) MX364519B (da)
PE (1) PE20161380A1 (da)
PH (1) PH12016501938A1 (da)
PL (1) PL3126354T3 (da)
PT (1) PT3126354T (da)
RS (1) RS60017B1 (da)
RU (1) RU2692808C2 (da)
SG (1) SG11201608190YA (da)
SI (1) SI3126354T1 (da)
SM (1) SMT202000132T1 (da)
SV (1) SV2016005297A (da)
TW (1) TWI664178B (da)
UA (1) UA119166C2 (da)
WO (1) WO2015150254A1 (da)
ZA (1) ZA201606566B (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2016009521A0 (en) 2014-04-04 2016-10-31 Lundbeck & Co As H Halogenated quinazolin-thf-amines as pde1 inhibitors
AU2017388054B2 (en) 2016-12-28 2022-03-24 Dart Neuroscience, Llc Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors
CA3120971A1 (en) 2017-11-27 2019-05-31 Dart Neuroscience, Llc Substituted furanopyrimidine compounds as pde1 inhibitors
CN112189013A (zh) 2018-05-25 2021-01-05 细胞内治疗公司 有机化合物
CN117105809B (zh) * 2023-10-20 2024-05-03 中国农业大学 一种苯甲酰苯胺化合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10042058A1 (de) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
GB0229281D0 (en) * 2002-12-16 2003-01-22 Novartis Ag Organic compounds
ZA200507979B (en) * 2003-03-03 2007-03-28 Vertex Pharma Inc Quinazolines useful as modulators of ion channels
GB0327319D0 (en) * 2003-11-24 2003-12-24 Pfizer Ltd Novel pharmaceuticals
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
US20090023756A1 (en) * 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
US20070265258A1 (en) * 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
JP2013505909A (ja) * 2009-09-24 2013-02-21 ビーエーエスエフ ソシエタス・ヨーロピア 無脊椎動物害虫を駆除するためのアミノキナゾリン化合物
US20130116241A1 (en) * 2011-11-09 2013-05-09 Abbvie Inc. Novel inhibitor compounds of phosphodiesterase type 10a
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
CA2943013A1 (en) 2014-04-04 2015-10-08 F. Hoffmann-La Roche Ag Pyridine-2-amides useful as cb2 agonists
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
AP2016009521A0 (en) 2014-04-04 2016-10-31 Lundbeck & Co As H Halogenated quinazolin-thf-amines as pde1 inhibitors
TW201625605A (zh) 2014-04-04 2016-07-16 賽諾菲公司 用於治療糖尿病、肥胖、血脂異常及相關病症之作為ｇｐｒ１１９調節劑的經取代之稠合雜環類
CR20160459A (es) 2014-04-04 2016-12-02 Eidgenoessische Technische Hochschule Zuerich Nuevos derivados de piridina
TW201623286A (zh) 2014-04-04 2016-07-01 賽諾菲公司 作為ｇｐｒ１１９調控劑用於治療糖尿病、肥胖、血脂異常及相關病症之異吲哚啉酮化合物

Also Published As

Publication number Publication date
CN106132953B (zh) 2019-03-22
GEP20186920B (en) 2018-11-12
CY1122784T1 (el) 2021-05-05
HRP20200369T1 (hr) 2020-08-07
CN106132953A (zh) 2016-11-16
DOP2016000263A (es) 2016-11-30
CL2016002515A1 (es) 2016-12-16
EP3126354B1 (en) 2020-01-22
JP2017509680A (ja) 2017-04-06
SMT202000132T1 (it) 2020-05-08
EA032579B1 (ru) 2019-06-28
GT201600213A (es) 2019-07-29
TW201620901A (zh) 2016-06-16
JP6554116B2 (ja) 2019-07-31
US20170022186A1 (en) 2017-01-26
AP2016009521A0 (en) 2016-10-31
RU2016138743A3 (da) 2019-01-15
RU2016138743A (ru) 2018-05-07
PT3126354T (pt) 2020-03-17
RS60017B1 (sr) 2020-04-30
TWI664178B (zh) 2019-07-01
CN109999039A (zh) 2019-07-12
AU2015239696B2 (en) 2019-10-24
CR20160463A (es) 2017-03-06
SI3126354T1 (sl) 2020-04-30
RU2692808C2 (ru) 2019-06-27
PH12016501938A1 (en) 2017-02-06
UA119166C2 (uk) 2019-05-10
CA2943011A1 (en) 2015-10-08
MX2016012955A (es) 2016-12-07
WO2015150254A1 (en) 2015-10-08
EA201691773A1 (ru) 2017-01-30
US10005764B2 (en) 2018-06-26
MX364519B (es) 2019-04-30
MA39837B1 (fr) 2020-05-29
AR101155A1 (es) 2016-11-30
ZA201606566B (en) 2017-11-29
ECSP16082599A (es) 2017-02-24
JO3628B1 (ar) 2020-08-27
US10526319B2 (en) 2020-01-07
ES2776359T3 (es) 2020-07-30
IL248078B (en) 2018-11-29
AU2015239696A1 (en) 2016-10-06
SG11201608190YA (en) 2016-10-28
PL3126354T3 (pl) 2020-06-15
LT3126354T (lt) 2020-03-25
SV2016005297A (es) 2016-11-30
PE20161380A1 (es) 2017-01-15
EP3126354A1 (en) 2017-02-08
US20190144434A1 (en) 2019-05-16
KR20160138084A (ko) 2016-12-02

Similar Documents

Publication Publication Date Title
LT3137169T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3105218T3 (da) Cyclopropylaminer som lsd1-inhibitorer
DK3105226T3 (da) Cyclopropylaminer som lsd1-inhibitorer
LT3303334T (lt) Tirozinkinazės inhibitoriai
HUE042335T2 (hu) ROR-gamma dihidropirrolopiridin inhibitorai
HUE050564T2 (hu) Lizinspecifikus demetiláz-1 inhibitorai
LT3511319T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3442972T3 (da) Bromdomænehæmmere
EP3723320C0 (en) SIMPLE RACH (SRACH)
BR112017000042A2 (pt) inibidores de desmetilase-1 lisina-específica
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3288944T3 (da) Imidazopyrazinoner som pde1-inhibitorer
DK3341379T3 (da) EZH2-hæmmere
DK3125898T3 (da) Farmakofor til trail-induktion
DK3186242T3 (da) Alfa-amino-beta-carboxymuconsyre-semialdehyd-decarboxylasehæmmere
CL2015001019S1 (es) Ampolleta
DK3114120T3 (da) Tetrazolon-substituerede dihydropyridinon-mgat2-hæmmere
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
HUE043622T2 (hu) Tároló
DK3126354T3 (da) Halogenerede quinazolin-thf-aminer som pde1-inhibitorer
DK3481826T3 (da) Tyrosinkinaseinhibitorer
DK3148513T3 (da) Ceritinib-formulering
DK3233839T3 (da) Heterocyclylkoblede imidazopyridazinderivater som pi3k-beta-inhibitorer
DK3193856T3 (da) Formulering